Company: SHPH
Filing Date: 2025-01-24
Form Type: 424B3
Source: 0001493152-25-003508
Chunk: 171

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-01-24
Form: 424B3
Chunk 171
---
 in an orderly transaction between market participants as of the measurement date. The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs to value its financial instruments:

| ● | Level                                                                                                                                  
 1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments.                                     |
| ● | Level                                                                                                                                  
 2: Quoted prices for similar instruments that are directly or indirectly observable in the marketplace.                                |
| ● | Level                                                                                                                                  
 3: Significant unobservable inputs which are supported by little or no market activity and that are financial instruments whose values 
 are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which       
 the determination of fair value requires a significant judgment or estimation.                                                         |

Financial instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires the Company to make judgments and consider factors specific to the asset or liability. The use of different assumptions and/or estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed, or initial amounts recorded, may not be indicative of the amount that the Company or holders of the instruments could realize in a current market exchange.

| F-9 |

The carrying amounts of the Company’s financial instruments including cash and cash equivalents, prepaid expenses, accounts payable and accrued liabilities approximate fair value due to the short-term maturities of these instruments.

Set out below are the Company’s financial instruments that are required to be remeasured at fair value on a recurring basis and their fair value hierarchy as of September 30, 2024 and December 31, 2023:

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

| September 30, 2024                         |     | Level 1 |   |     | Level 2 |   |     | Level 3 |        |     | Carrying Value |        |
|:-------------------------------------------|:----|:--------|:--|:----|:--------|:--|:----|:--------|-------:|:----|:---------------|-------:|
| Assets                                     |     |         |   |     |         |   |     |         |        |     |                |        |
| Marketable Securities:                     |     |         |   |     |